GLP-1 and Muscle Loss: How Much of the Weight Is Lean Mass
Lean mass is roughly a quarter to two-fifths of the weight lost on semaglutide and tirzepatide. Whether that figure is alarming depends entirely on what you compare it against.
GLP-1 & Metabolic
6 articles
The incretin drugs, what their trials actually showed, and the questions the headlines skip.
The GLP-1 Plateau: What the Trial Curves Actually Show
Semaglutide and tirzepatide weight curves flatten months before the trials end. That flattening is energy balance settling at a new equilibrium, not the drug wearing off.
Oral vs Injectable Semaglutide: The Absorption Problem
Oral and injectable semaglutide are the same peptide. Only about one percent of a swallowed dose is absorbed, and that single fact explains the tablet strengths, the fasting rule and the variability.
Retatrutide: What the Trials Show and What They Do Not
Retatrutide's phase 2 results are the largest average weight reductions yet reported for a drug. They also come from a 48-week mid-stage trial in a few hundred people, with no outcome data and no approval anywhere.
Semaglutide vs Tirzepatide: What the Head-to-Head Data Shows
Two randomised trials have compared these drugs directly, one in type 2 diabetes and one in obesity. Both favoured tirzepatide. Here is what each actually measured, and what it does not settle.
What Happens When You Stop a GLP-1
Stop a GLP-1 and the weight comes back. The STEP 1 extension, STEP 4 and SURMOUNT-4 measured how much returns, how fast, and what happens to blood pressure, lipids and glucose as it does.